BL LATANOPROST SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

LATANOPROST

제공처:

BAUSCH & LOMB INC

ATC 코드:

S01EE01

INN (국제 이름):

LATANOPROST

복용량:

50MCG

약제 형태:

SOLUTION

구성:

LATANOPROST 50MCG

관리 경로:

OPHTHALMIC

패키지 단위:

2.5ML

처방전 유형:

Prescription

치료 영역:

PROSTAGLANDIN ANALOGS

제품 요약:

Active ingredient group (AIG) number: 0132916002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2013-04-02

제품 특성 요약

PRODUCT MONOGRAPH
PR
BL LATANOPROST
Latanoprost Ophthalmic Solution
50 mcg/mL
PROSTAGLANDIN F2Α ANALOGUE
BAUSCH & LOMB INCORPORATED DATE OF REVISION:
1400 North Goodman Street
June 30, 2022
Rochester NY, USA
14609
Imported and Distributed by:
BAUSCH + LOMB CORPORATION
520 Applewood Crescent
Vaughan, Ontario
L4K 4B4
Control #: 260462
_Pr_
_BL LATANOPROST Product Monograph _
_Page 2 of 28_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION..............................................................................
3
INDICATIONS
AND
CLINICAL
USE
...................................................................................
3
CONTRAINDICATIONS.......................................................................................................
3
WARNINGS
AND
PRECAUTIONS
......................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................
6
DRUG
INTERACTIONS
.......................................................................................................
7
DOSAGE
AND
ADMINISTRATION
.....................................................................................
7
OVERDOSAGE.....................................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY
.................................................................... 9
STORAGE
AND
STABILITY
...............................................................................................10
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING .....................................................10
PART II: SCIENTIFIC INFORMATION
.............................................................................
11
PHARMACEUTICAL
INFORMATION................................................................................11
CLINICAL
TRIALS
.........................